Feifei Luo

Feifei Luo

Auto-generated profile, based on publicly available information

Feifei Luo

Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong , Hong Kong

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2025 in Neuro-Oncology
Verified
Journal Article
Closed access
FLFeifei Luo
Feifei Luo
YMYan Mei
Yan Mei
YLYanwen Li
Yanwen Li
JYJiahao Yang
Jiahao Yang
SXShaoyan Xi
Shaoyan Xi
HChaiping cai
haiping cai
Background: The effectiveness of PD-1/PD-L1 immune checkpoint blockade therapy in glioblastoma (GBM) is limited due to the tumor immunosuppressive microenvironment (TIME). Therefore, strategies of reprogramming TIME to a pro-inflammatory state offer a promising therapeutic approach. Methods: We applied bioinformatics analysis of single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (stRNA-seq) to identify a significant accumulation of cancer-associated fibroblasts (CAFs) subclusters with elevated LRRC15 expression in the nonresponders to anti-PD-1 therapy. The molecular mechanism of LRRC15 was functionally validated in vitro and in vivo. Results: These CAFs subclusters drive the infiltration of macrophages (Mφ) into the tumor microenvironment and promote their polarization toward the M2 phenotype. Deletion of Lrrc15 in CAFs significantly restrained tumor growth and prolonged survival in mouse models. Mechanistically, LRRC15 in CAFs promotes IL8 expression by activating the downstream FAK/SRC/NF-κB pathways, leading to Mφ migration and M2-like polarization. In turn, M2-like Mφs secrete TGF-β, which induces LRRC15 expression in CAFs via SMAD2-dependent transcriptional activation. Targeting CAFs subcluster with elevated LRRC15 expression in combination with anti-PD-1 treatment enhanced antitumor efficacy. Conclusions: Our findings suggest that targeting LRRC15 may provide a novel strategy to augment anti-PD-1 therapy and overcome immunotherapy resistance in GBM.

17 January 2023 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
FLFeifei Luo
Feifei Luo
YLYifu Liao
Yifu Liao
ECEndong Cao
Endong Cao
YYYong Yang
Yong Yang
KTKai Tang
Kai Tang
HChaiping cai
haiping cai
Introduction: Glioma is the most common primary tumor in the central nervous system, and prognostic biomarkers are still lacking. HIC ZBTB transcriptional repressor 2 (HIC2) is a hypermethylated gene that plays an important functional role in cardiac development. However, the actual role of HIC2 in glioma progression remains unclear. This study aimed to investigate the function of HIC2 and whether it could be a prognostic biomarker in glioma.Methods: The DNA methylation and mRNA expression profiles of HIC2 were downloaded from public databases. The prognostic prediction ability and mechanism research of HIC2 were evaluated.Results: We found that HIC2 was hypermethylated and expressed at low levels in glioma samples. Hypermethylation and low expression of HIC2 predicted poor prognosis. Multivariate Cox regression analysis suggested that HIC2 was an independent prognostic factor for gliomas. Co‐IP assays demonstrated that HIC2 interacts with RNF44, and dual‐luciferase reporter assays and ChIP assays revealed that HIC2 transcriptionally inhibits PTPRN2 expression.Conclusions: Our findings suggest that HIC2 represents a tumor suppressor gene and prognostic biomarker for glioma progression and that overexpression of HIC2 inhibits the proliferation of glioma in vitro and in vivo by interacting with RNF44 and PTPRN2.

1 February 2021 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
LCLi Cao
Li Cao
FLFei‐Fei Luo
Fei‐Fei Luo
HHHong‐Bin Huang
Hong‐Bin Huang
THTie‐Jun Huang
Tie‐Jun Huang
HHHao Hu
Hao Hu
BHBi-Jun Huang
Bi-Jun Huang
Click on the article title to read more.